Developer docs
API playgroundTry for free, no card

Search company profiles

IPD Analytics

Full company profile

uuid0007oo1

Namestring
IPD Analytics
Legal namestring
IPD Analytics, LLC
Company typeenum
Private
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAventura, United States
HQ citystring
Aventura
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug life-cycle insights, pharmaceutical market intelligence, patent analytics platform, healthcare market research, drug pipeline forecasting
Industry1 code
PRIMARYBPAHAMAG
IP Due Diligence & Freedom-to-Operate (FTO) Analysis
NAICS code1 code
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
Pharmaceutical Market Intelligence
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Subscription-Based Platform Access
TypeSubscription Recurring
Description

IPD Analytics offers subscription-based access to proprietary platforms providing comprehensive drug life-cycle analysis, payer and formulary management guidance, market access intelligence, clinical pipeline tracking, and other insights for healthcare decision-makers.

ipdanalytics.com
2Consultations
TypeProfessional Services
Description

Direct consultations with IPD's expert team including clinical pharmacists, forecasters, and legal analysts available to subscribers.

ipdanalytics.com
3Email Alerts
TypeSubscription Recurring
Description

Real-time email alerts delivering critical headlines, day-by-day trial updates, and key litigation updates to subscribers.

ipdanalytics.com
4Reports and Data Downloads
TypeSubscription Recurring
Description

Comprehensive reports and data downloads including drug pipeline reports, market impact forecasts, and curated datasets available to subscribers.

ipdanalytics.com
5Podcast Content
TypeSubscription Recurring
Description

IPD's Drug & Clinical Review podcast episodes featuring expert discussions on drug intelligence and management strategy.

ipdanalytics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Subscription-based access to proprietary platforms and insights
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing tailored to organizational needs. No public pricing tiers or specific amounts disclosed.

ipdanalytics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

IPD Analytics operates a subscription-based intelligence platform that identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market. It aggregates data from thousands of sources, combines it with proprietary research, and delivers drug life-cycle analysis, loss-of-exclusivity timing, market impact forecasts, clinical pipeline tracking, formulary and reimbursement insights, and patent landscape intelligence through an online platform, email alerts, consultations, reports, data downloads, and podcasts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Analysis of 141 brand drugs across 40 manufacturers for patent exclusivity retention study
+4 more records
Product overview1 text field

IPD Analytics operates as a subscription-based intelligence platform offering a comprehensive suite of pharmaceutical market analysis tools. The core platform consists of multiple integrated modules organized into four key capability areas: Life-Cycle Insights (including regional variants for U.S., Global, and 12 international markets covering Europe, Japan, Canada, Australia, Brazil, Mexico, India, Korea, Russia, China, Taiwan, and Saudi Arabia), Payer and Provider Insights (encompassing Access Hub, Payer & Provider Insights, Coding & Reimbursement, Budget Impact, and Primary Market Insights), Market and Financial Insights (including Market & Financial Insights, Rebate Monitor, and Portfolio and Formulation Insights), and Supporting Solutions (including Global Patent Search/GPS, Data STACK for curated datasets and visualizations, Legislation & Government Insights, Med-Tech Insights, and Product Liability Insights). The platform delivers insights through multiple formats including the online platform, email alerts, direct consultations, reports, podcast episodes, and data downloads. The company serves brand manufacturers, generic manufacturers, specialty drug manufacturers, active ingredient suppliers, payers, health systems, wholesalers, pharmacies, PBMs, GPOs, IDNs, institutional investors, and other pharmaceutical stakeholders.

Product and service1 record
1U.S. Life-Cycle Insights
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

AMCP announced a strategic partnership with IPD Analytics in April 2026. Through this partnership, select AMCP staff will have access to IPD Analytics' platform and insights, which AMCP will use to inform resources developed for their members. This collaboration enhances understanding of market dynamics, formulary trends, pharmacy cost considerations, and key market catalysts, supporting informed decision-making across healthcare stakeholders.

Strategic tierMinorTypeOthers
Description

IPD Analytics data is used by ICER as one of multiple drug pricing data sources (such as SSR Health, IPD Analytics, and Federal Supply Schedule) in their Launch Price and Access Report analyzing launch prices and patient access for new FDA-approved treatments. IPD's proprietary pricing data contributes to ICER's evidence-based reviews of healthcare interventions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GlobalData is a broader pharma and healthcare intelligence incumbent that overlaps IPD's pipeline, pricing, and market access coverage, offering a wider portfolio that competes for the same enterprise pharma intelligence budget.

TypeBroad incumbent
Description

IQVIA is the dominant broad incumbent in pharma data, clinical, and commercial intelligence; it competes with IPD at the top end of enterprise pharma accounts, offering much broader data assets and global scale.

3ZS Associates
TypeEmerging player
Description

ZS Associates competes with IPD in payer and provider market access analytics, with a heavier consulting overlay and overlapping pharma client base for value, access, and pricing strategy work.

TypeDirect peer
Description

PatentSight is a direct competitor in patent landscape analytics, directly overlapping IPD's Global Patent Search (GPS) and Paragraph IV / Orange Book analysis use cases for pharma IP teams.

TypeDirect peer
Description

Norstella's Evaluate franchise is a direct competitor to IPD Analytics in drug life-cycle forecasting, market impact analysis, and consensus sales forecasts for brand and generic drugs, serving a highly overlapping pharma manufacturer and investor customer base.

TypeDirect peer
Description

Citeline is a direct competitor covering drug pipeline intelligence, clinical trial tracking, and competitive landscape analysis — the same core use cases IPD serves through its Drug Pipeline and Life-Cycle Insights modules.

TypeDirect peer
Description

Clarivate's Cortellis and IP-related products directly overlap IPD's Global Patent Search (GPS) and life-cycle insight offerings, competing for the same pharma IP and competitive intelligence budgets.

TypeDirect peer
Description

DRG competes with IPD in market access intelligence, payer/provider insights, and drug forecasting — a comparable subscription intelligence model targeting pharma and biotech commercial teams.

TypeDirect peer
Description

SSR Health is a direct competitor specifically in drug pricing and rebate analytics — co-cited with IPD as a source by ICER in launch price and access reports.

10Bloomberg Intelligence
TypeBroad incumbent
Description

Bloomberg Intelligence competes with IPD's Market & Financial Insights module, particularly for institutional investor and hedge fund subscribers seeking pharma forecasting and competitive landscape analysis.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IPD Analytics

Pharmaceutical Market Intelligenceipdanalytics.com

IPD Analytics firmographics

Firmographics
Name
IPD Analytics
Legal name
IPD Analytics, LLC
Website
https://ipdanalytics.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

IPD Analytics industry classification

Industry
Product category
Pharmaceutical Market Intelligence
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYBPAHAMAG
IP Due Diligence & Freedom-to-Operate (FTO) Analysis

Keywords

  • Drug life-cycle insights
  • Pharmaceutical market intelligence
  • Patent analytics platform
  • Healthcare market research
  • Drug pipeline forecasting

Where IPD Analytics is headquartered

Location

Headquarters

HQ city
Aventura
HQ country
United States
HQ region
North America

Offices1 record

Markets served

IPD Analytics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription-Based Platform Access: IPD Analytics offers subscription-based access to proprietary platforms providing comprehensive drug life-cycle analysis, payer and formulary management guidance, market access intelligence, clinical pipeline tracking, and other insights for healthcare decision-makers.
  2. Consultations: Direct consultations with IPD's expert team including clinical pharmacists, forecasters, and legal analysts available to subscribers.
  3. Email Alerts: Real-time email alerts delivering critical headlines, day-by-day trial updates, and key litigation updates to subscribers.
  4. Reports and Data Downloads: Comprehensive reports and data downloads including drug pipeline reports, market impact forecasts, and curated datasets available to subscribers.
  5. Podcast Content: IPD's Drug & Clinical Review podcast episodes featuring expert discussions on drug intelligence and management strategy.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based access to proprietary platforms and insights

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

IPD Analytics product offering

Product offering

Core offering

IPD Analytics operates a subscription-based intelligence platform that identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market. It aggregates data from thousands of sources, combines it with proprietary research, and delivers drug life-cycle analysis, loss-of-exclusivity timing, market impact forecasts, clinical pipeline tracking, formulary and reimbursement insights, and patent landscape intelligence through an online platform, email alerts, consultations, reports, data downloads, and podcasts.

Product overview

IPD Analytics operates as a subscription-based intelligence platform offering a comprehensive suite of pharmaceutical market analysis tools. The core platform consists of multiple integrated modules organized into four key capability areas: Life-Cycle Insights (including regional variants for U.S., Global, and 12 international markets covering Europe, Japan, Canada, Australia, Brazil, Mexico, India, Korea, Russia, China, Taiwan, and Saudi Arabia), Payer and Provider Insights (encompassing Access Hub, Payer & Provider Insights, Coding & Reimbursement, Budget Impact, and Primary Market Insights), Market and Financial Insights (including Market & Financial Insights, Rebate Monitor, and Portfolio and Formulation Insights), and Supporting Solutions (including Global Patent Search/GPS, Data STACK for curated datasets and visualizations, Legislation & Government Insights, Med-Tech Insights, and Product Liability Insights). The platform delivers insights through multiple formats including the online platform, email alerts, direct consultations, reports, podcast episodes, and data downloads. The company serves brand manufacturers, generic manufacturers, specialty drug manufacturers, active ingredient suppliers, payers, health systems, wholesalers, pharmacies, PBMs, GPOs, IDNs, institutional investors, and other pharmaceutical stakeholders.

Differentiator

Problem solved

Functional benefit

Products and services

  • U.S. Life-Cycle Insights

Quantifiable outcome

  • Analysis of 141 brand drugs across 40 manufacturers for patent exclusivity retention study
  • +4 more outcomes

Companies that use IPD Analytics

Customer profile

Named customers7 records

Segments8 records

Ideal customer profiles5 records

IPD Analytics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

IPD Analytics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Academy of Managed Care Pharmacy (AMCP)coreStrategic or Co-development Partner · 7 April 2026AMCP announced a strategic partnership with IPD Analytics in April 2026. Through this partnership, select AMCP staff will have access to IPD Analytics' platform and insights, which AMCP will use to inform resources developed for their members. This collaboration enhances understanding of market dynamics, formulary trends, pharmacy cost considerations, and key market catalysts, supporting informed decision-making across healthcare stakeholders.
  • Institute for Clinical and Economic Review (ICER)minorOthersIPD Analytics data is used by ICER as one of multiple drug pricing data sources (such as SSR Health, IPD Analytics, and Federal Supply Schedule) in their Launch Price and Access Report analyzing launch prices and patient access for new FDA-approved treatments. IPD's proprietary pricing data contributes to ICER's evidence-based reviews of healthcare interventions.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

IPD Analytics competitors and assessment

Company assessment

Broad incumbents

  • GlobalData: GlobalData is a broader pharma and healthcare intelligence incumbent that overlaps IPD's pipeline, pricing, and market access coverage, offering a wider portfolio that competes for the same enterprise pharma intelligence budget.
  • IQVIA: IQVIA is the dominant broad incumbent in pharma data, clinical, and commercial intelligence; it competes with IPD at the top end of enterprise pharma accounts, offering much broader data assets and global scale.
  • Bloomberg Intelligence: Bloomberg Intelligence competes with IPD's Market & Financial Insights module, particularly for institutional investor and hedge fund subscribers seeking pharma forecasting and competitive landscape analysis.

Emerging players

  • ZS Associates: ZS Associates competes with IPD in payer and provider market access analytics, with a heavier consulting overlay and overlapping pharma client base for value, access, and pricing strategy work.

Direct peers

  • PatentSight (LexisNexis): PatentSight is a direct competitor in patent landscape analytics, directly overlapping IPD's Global Patent Search (GPS) and Paragraph IV / Orange Book analysis use cases for pharma IP teams.
  • Norstella (Evaluate Pharma): Norstella's Evaluate franchise is a direct competitor to IPD Analytics in drug life-cycle forecasting, market impact analysis, and consensus sales forecasts for brand and generic drugs, serving a highly overlapping pharma manufacturer and investor customer base.
  • Citeline (Pharma Intelligence, Informa): Citeline is a direct competitor covering drug pipeline intelligence, clinical trial tracking, and competitive landscape analysis — the same core use cases IPD serves through its Drug Pipeline and Life-Cycle Insights modules.
  • Clarivate: Clarivate's Cortellis and IP-related products directly overlap IPD's Global Patent Search (GPS) and life-cycle insight offerings, competing for the same pharma IP and competitive intelligence budgets.
  • DRG (Decision Resources Group): DRG competes with IPD in market access intelligence, payer/provider insights, and drug forecasting — a comparable subscription intelligence model targeting pharma and biotech commercial teams.
  • SSR Health: SSR Health is a direct competitor specifically in drug pricing and rebate analytics — co-cited with IPD as a source by ICER in launch price and access reports.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

IPD Analytics social profiles

Digital presence

IPD Analytics compliance and trust

Trust signal

Compliance1 record

IPD Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IPD Analytics leadership team

Management profile

Number of profiles

Profiles3 records

IPD Analytics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IPD Analytics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IPD Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IPD Analytics

What does IPD Analytics do?

IPD Analytics operates a subscription-based intelligence platform that identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market. It aggregates data from thousands of sources, combines it with proprietary research, and delivers drug life-cycle analysis, loss-of-exclusivity timing, market impact forecasts, clinical pipeline tracking, formulary and reimbursement insights, and patent landscape intelligence through an online platform, email alerts, consultations, reports, data downloads, and podcasts.

Is IPD Analytics a public or private company?

IPD Analytics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IPD Analytics founded?

IPD Analytics was founded in 2002. It employs 251 to 500 people.

Where is IPD Analytics based?

IPD Analytics is headquartered in Aventura, United States, in the North America region.

How does IPD Analytics make money?

Five revenue lines are on record. Subscription-Based Platform Access are the primary driver. The others are consultations, email Alerts, reports and Data Downloads and podcast Content.

Who are IPD Analytics's main competitors?

Broad incumbents on record are GlobalData, IQVIA and Bloomberg Intelligence. ZS Associates is listed as an emerging player. Direct peers are PatentSight (LexisNexis), Norstella (Evaluate Pharma), Citeline (Pharma Intelligence, Informa), Clarivate, DRG (Decision Resources Group) and SSR Health.

Does IPD Analytics have an API?

No public API is recorded for IPD Analytics.

What industry is IPD Analytics in?

IPD Analytics's product category is Pharmaceutical Market Intelligence. Its primary akta.pro industry code is BPAHAMAG, IP Due Diligence & Freedom-to-Operate (FTO) Analysis. Its NAICS code is 5182 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IpdanalyticsCell and Gene Therapy Pipeline 2H 2025IPD Analytics has released its latest pipeline report analyzing 17 cell and gene therapies with potential for approval within the next year, with estimated costs per treatment ranging from $500,000 to $4 million.IpdanalyticsUS Pharmaceutical Pipeline Expansion With Innovation and CompetitionIPD Analytics presented projections for the 2025 US pharmaceutical pipeline at the Academy of Managed Care Pharmacy annual meeting, highlighting a surge in generics, biosimilars, and innovative therapies. The report details 20 small molecule drugs expected to face generic competition and nine new drug applications awaiting FDA approval under the 505(b)(2) pathway. Additionally, the article outlines upcoming biosimilar launches and gene therapies for various conditions, noting that FDA approvals have returned to pre-pandemic levels.IpdanalyticsBiosimilar Pipeline ReportIPD Analytics released its Biosimilar Pipeline Report for 1H 2025, outlining potential approvals and launches through the 2028 horizon. The report notes that the FDA approved 18 new biosimilars in 2024, which are driving cost savings by lowering average sales prices for reference medical-benefit products.IpdanalyticsIntroduction to Digital Therapeutics and Potential Payer ManagementAn IPD Analytics article explains digital therapeutics, software-based interventions that deliver evidence-based treatments for conditions such as addiction, depression, anxiety and type 2 diabetes, often via cognitive behavioral therapy delivered through mobile apps. It notes barriers including limited payer coverage, FDA 510(k) and De Novo pathways, and lack of standardized reimbursement. The authors argue more rigorous clinical evidence, physician support and patient demand could drive wider coverage.